Axcelis Technologies Inc. Common Stock (NASDAQ:ACLS)

Real-time price: | Most recent change:0.00%

Axcelis Technologies is a leading producer of ion implantation equipment used in the fabrication of semiconductors. The company also produces dry strip, photostabilization and rapid thermal processing equipment, which is used in semiconductor manufacturing primarily before and after the ion implantation process. In addition, the company provides extensive aftermarket service and support, including spare parts, equipmentupgrades, maintenance services and customer training....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 19 September 2026

Blog+More

Fundamental factors often reflect macroeconomic innovations and so help inform better stock investment decisions.

Jacob Miramar

2019-08-22 11:35:00 Thursday ET

Fundamental factors often reflect macroeconomic innovations and so help inform better stock investment decisions.

Fundamental factors often reflect macroeconomic innovations and so help inform better stock investment decisions. Nobel Laureate Eugene Fama and his long-ti

+See More

The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases.

Laura Hermes

2019-10-17 08:35:00 Thursday ET

The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases.

The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases. The ECB commits to further cutt

+See More

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Olivia London

2017-11-27 07:39:00 Monday ET

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Is it anti-competitive and illegal for passive indexers and mutual funds to place large stock bets in specific industries with high market concentration? Ha

+See More

Several recent events explain why Trump may undermine multilateral world order.

Joseph Corr

2018-06-03 07:35:00 Sunday ET

Several recent events explain why Trump may undermine multilateral world order.

Several recent events explain why Trump may undermine multilateral world order. First, Trump withdraws the U.S. from the 12-nation Trans-Pacific Partnership

+See More

The Economist suggests that the world has learned few lessons of the global financial crisis from 2008 to 2009.

Becky Berkman

2018-09-07 07:33:00 Friday ET

The Economist suggests that the world has learned few lessons of the global financial crisis from 2008 to 2009.

The Economist re-evaluates the realistic scenario that the world has learned few lessons of the global financial crisis from 2008 to 2009 over the past deca

+See More

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

Monica McNeil

2025-10-31 12:26:00 Friday ET

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

With respect to wider weight loss treatment and obesity treatment, the global market for GLP-1 medications now grows substantially to benefit more than 1 bi

+See More